Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience

Autor:	Eduardo Minelli, Paulo Augusto de Arruda Mello Filho, Laurentino Biccas Neto, Oswaldo Ferreira Moura Brasil, Mauricio Maia, Claudio Dalloul, André Maia, Gabriel Costa de Andrade, Matias Iglicki, Acacio Muralha Neto
Rok vydání:	2018
Předmět:	Adult Male Intraocular pressure medicine.medical_specialty Visual acuity genetic structures Visual Acuity 01 natural sciences Dexamethasone Macular Edema 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endophthalmitis Cataracts Ophthalmology medicine Humans 0101 mathematics Adverse effect Glucocorticoids Aged Retrospective Studies Aged 80 and over Drug Implants Diabetic Retinopathy business.industry 010102 general mathematics Retinal General Medicine Middle Aged medicine.disease eye diseases Sensory Systems Treatment Outcome chemistry Intravitreal Injections 030221 ophthalmology & optometry Female sense organs Implant medicine.symptom business Follow-Up Studies medicine.drug
Zdroj:	Ophthalmologica. 241:9-16
ISSN:	1423-0267 0030-3755
Popis:	Introduction: There are few real-life studies on the intravitreal 0.7-mg dexamethasone implant for the treatment of diabetic macular edema (DME) conducted in Latin America. We aimed to assess the effectiveness and safety of this implant in clinical practice. Methods: Twenty-seven centers from Brazil and one from Argentina provided information on patients with DME treated with Ozurdex. The efficacy outcome variables were best-corrected visual acuity (BCVA) in Snellen and central retinal thickness (CRT). Safety was assessed by the elevation in intraocular pressure (IOP), occurrence of cataracts, and adverse events. Results: A total of 329 eyes (both treated cases and naïve eyes) from 282 patients underwent treatment. The time since diagnosis of DME ranged from 1 to 156 months. The median BCVA was 0.7 logMAR/50 letters at baseline and 0.3 logMAR/70 letters after treatment (both p < 0.001). Median CRT values decreased from 425 µm at baseline to 270 µm after treatment (p < 0.001). Increases in IOP of at least 10 mm Hg were observed in 7.4% of eyes, and 4% of eyes had cataract evolution. No cases of endophthalmitis were reported. Conclusion: These real-life results suggest that the intravitreal dexamethasone implant is effective and safe for eyes with DME.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5594dd63727588b42ab78958e0de2c34 https://doi.org/10.1159/000492132 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.